All Stories

  1. Acute exacerbation in fibrotic interstitial lung disease: an international working group report
  2. Combination Therapy in Pulmonary Fibrosis: A New Era
  3. “I just know I don’t know”: challenging the interpretation of clinical trials grounded in imperfect assumptions
  4. End-user global study to identify countries’ challenges and solutions in the uptake and implementation of new tuberculosis treatment regimens
  5. Targeting Vascular Inflammation In Patients with Community-Acquired Pneumonia (TIN-CAP): protocol for a multicentre, randomised, double-blind, placebo-controlled trial
  6. Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma
  7. Exploring the temporal relationship between stigma, disease manifestations, and health outcomes in post COVID-19 condition: a longitudinal descriptive study
  8. The effect of pollutant exposure on cough in progressive pulmonary fibrosis
  9. Which trial do we need? Combination regimen for individuals exposed to multidrug-resistant Mycobacterium tuberculosis
  10. Impact of Clinical Practice Guidelines on Palliative Care and Health Outcomes in Idiopathic Pulmonary Fibrosis in a Canadian Province
  11. Decoding objective cough features in progressive pulmonary fibrosis: A 6-month feasibility study
  12. Patient and provider perceptions of the impact of COVID-19 on tuberculosis healthcare access and delivery: A qualitative study of the complexities of a pandemic within a pandemic
  13. The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation
  14. Refining the definition of miliary/disseminated tuberculosis in Canada
  15. Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases
  16. “A Mighty Flame Can Follow a Tiny Spark”: Is This the Case of c-Jun N-Terminal Kinase 1 Inhibitors in Idiopathic Pulmonary Fibrosis?
  17. Understanding facilitators and barriers to oxygen therapy for patients with interstitial lung disease
  18. Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?
  19. Factors associated with phenotypes of dyspnea in post-COVID-19 condition: a cross-sectional study
  20. The clinical impact of heart failure with preserved ejection fraction in interstitial lung diseases
  21. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study
  22. The diagnostic pathway for patients with interstitial lung disease: a mixed-methods study of patients and physicians
  23. Use of 6‐minute walk distance to predict lung transplant‐free survival in fibrosing non‐IPF interstitial lung diseases
  24. Early Organ Metastasis in Granulomatous Mycosis Fungoides: A Systematic Review
  25. Macrolides and Asthma Therapy
  26. Chapitre 15: Le suivi du rendement du programme de lutte antituberculeuse
  27. Characterizing long-COVID brain fog: a retrospective cohort study
  28. Less Social Deprivation Is Associated With Better Health-Related Quality of Life in Asthma and Is Mediated by Less Anxiety and Better Sleep Quality
  29. A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings
  30. Skin disorders and interstitial lung disease: Part II—The spectrum of cutaneous diseases with lung disease association
  31. Skin disorders and interstitial lung disease: Part I—Screening, diagnosis, and therapeutic principles
  32. Fibrotic or nonfibrotic interstitial lung disease in patients with primary Sjögren syndrome
  33. No one left behind: review of precision medicine and cystic fibrosis—how the changing approach to cystic fibrosis treatment might lead to tailored therapies for all
  34. Reliability and validity of the post COVID-19 condition stigma questionnaire: a prospective cohort study
  35. A case series of dermatomyositis following SARS-CoV-2 vaccination
  36. Reflecting on the relationship between residential schools and TB in Canada
  37. Responding to the post-pandemic crisis: post-exposure prophylaxis for TB
  38. Reference equations for oscillometry and their differences among populations: a systematic scoping review
  39. Persistent dyspnea after COVID-19 is not related to cardiopulmonary impairment; a cross-sectional study of persistently dyspneic COVID-19, non-dyspneic COVID-19 and controls
  40. Chapter 15: Monitoring tuberculosis program performance
  41. Immunomodulatory treatment of interstitial lung disease
  42. COVID‐19 hospitalization is associated with pulmonary/diffusion abnormalities but not post‐acute sequelae of COVID‐19 severity
  43. Macrolides versus placebo for chronic asthma
  44. Exertional intolerance and dyspnea with preserved lung function: an emerging long COVID phenotype?
  45. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management
  46. Disseminated TB: still being missed and misunderstood
  47. Six-minute walking test outweighs other predictors of mortality in idiopathic pulmonary fibrosis. A real-life study from the Swedish IPF registry
  48. Early referral to palliative care in IPF – pitfalls and opportunities in clinical trials
  49. RA-ILD: does more detailed radiological classification add something to our knowledge of this condition?
  50. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden
  51. What patients with Idiopathic Pulmonary Fibrosis and caregivers want – Filling the currents gaps with patient reported outcomes and experience measures
  52. Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015
  53. Pulmonary outcomes in adults with a history of Bronchopulmonary Dysplasia differ from patients with asthma
  54. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study
  55. An Atypical Case of Idiopathic Pulmonary Fibrosis in a Patient from Africa
  56. Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden
  57. Latent tuberculous infection among foreign-born individuals applying to shelters in the metropolitan area of Milan
  58. Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
  59. Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
  60. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study
  61. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
  62. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
  63. Lung function development after preterm birth in relation to severity of Bronchopulmonary dysplasia
  64. Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren’s syndrome using high-content peptide microarrays
  65. Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays
  66. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
  67. Need for combined interventions and operational research to tackle tuberculous meningitis
  68. Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
  69. T-Cell Therapy: Options for Infectious Diseases: Table 1.
  70. Macrolides for chronic asthma
  71. Recurrent respiratory infections and unusual radiology: a woman with Kartagener's syndrome
  72. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis
  73. Extra-pulmonary tuberculosis and Xpert® MTB/RIF: all about meta-analyses?
  74. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
  75. No association between Birt-Hogg-Dubé syndrome skin fibrofolliculomas and the first 10 described human polyomaviruses or human papillomaviruses
  76. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial
  77. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
  78. Chronic empyema: importance of preventing complications in the management of pleural effusions
  79. Isoniazid preventive treatment: predictors of adverse events and treatment completion
  80. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1–
  81. Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension
  82. Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections
  83. Risk factors associated with pulmonary tuberculosis
  84. Trends and challenges in tuberculosis in a medium-sized southern European setting [Notes from the field]
  85. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
  86. "Interferon-  release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis." R. Diel, D. Goletti, G. Ferrara, G. Bothamley, D. Cirillo, B. Kampmann, C. Lange, M. Losi, R. Markova, G.B. Migliori,...
  87. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  88. Tuberculosis in prisons: anatomy of global neglect
  89. Screening of immigrants in the UK for latent tuberculosis
  90. Xpert MTB/RIF test for tuberculosis
  91. A Decade of Interferon-γ Release Assays: Quest for the Holy Grail to Diagnose Latent Infection withMycobacterium tuberculosis?
  92. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis
  93. The best on infections: update from the 2010 ERS Congress
  94. Tuberculosis in prisons in sub-Saharan Africa – the need for improved health services, surveillance and control
  95. Interferon-  release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis
  96. TB or not TB: update from the ERS Respiratory Infection Assembly 10
  97. Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection
  98. Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients
  99. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
  100. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis
  101. Mycobacterium tuberculosis Induces CCL18 Expression in Human Macrophages
  102. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?
  103. Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TBassay
  104. Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results
  105. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
  106. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  107. Clinical and operational value of the extensively drug-resistant tuberculosis definition
  108. Combination fluticasone and salmeterol vesus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  109. Extensively Drug-resistant Tuberculosis, Italy and Germany
  110. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs
  111. Blood tests for diagnosis of tuberculosis – Authors' reply
  112. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study
  113. Macrolides for chronic asthma
  114. Routine Hospital Use of a New Commercial Whole Blood Interferon-γ Assay for the Diagnosis of Tuberculosis Infection
  115. Macrolides for chronic asthma
  116. Community Acquired Pneumonia in Internal Medicine: A One-Year Retrospective Study Based on Pneumonia Severity Index
  117. Macrolides in the treatment of asthma and cystic fibrosis
  118. Corticosteroids for idiopathic pulmonary fibrosis
  119. Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000
  120. Macrolides for chronic asthma